[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
作者信息
Zhang Q, Xiao Y
机构信息
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2022.09.014.
Abstract
摘要
相似文献
1
[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].[CD19嵌合抗原受体T细胞治疗弥漫性大B细胞淋巴瘤的复发机制及应对策略]
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2022.09.014.
2
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
3
Late Events After CD-19 CAR-T Treatment.CD-19嵌合抗原受体T细胞（CAR-T）治疗后的晚期事件
Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.
4
Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.嵌合抗原受体T细胞（CAR-T）用于弥漫性大B细胞淋巴瘤二线治疗中的未解决问题。
Nat Med. 2022 Dec;28(12):2458-2459. doi: 10.1038/s41591-022-02067-9.
5
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.一名患有难治性弥漫性大B细胞淋巴瘤且存在克隆性造血的患者在接受抗CD19嵌合抗原受体T细胞输注后不久发生急性髓系白血病。
Haematologica. 2023 Jan 1;108(1):290-294. doi: 10.3324/haematol.2022.281351.
6
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.在难治性弥漫性大B细胞淋巴瘤中，抗CD19嵌合抗原受体T细胞疗法后，PD-1抑制导致肿瘤快速消退。
Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.
7
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
8
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.T细胞/组织细胞丰富的大B细胞淋巴瘤对CD19导向的嵌合抗原受体T细胞疗法的原发性耐药
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
9
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.嵌合抗原受体T细胞疗法治疗HIV相关弥漫性大B细胞淋巴瘤：病例报告及管理建议
Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6.
10
CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.嵌合抗原受体T细胞（CAR-T）疗法作为大B细胞淋巴瘤二线治疗优于标准治疗：一项系统评价和荟萃分析。
Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25.
本文引用的文献
1
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.用于递送 CD19 CAR-T 细胞治疗大 B 细胞淋巴瘤的国家服务 - 英国真实世界经验。
Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29.
2
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.自体移植后复发/难治性侵袭性 B 细胞淋巴瘤患者的 CD19/CD22 嵌合抗原受体 T 细胞鸡尾酒疗法。
Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20.
3
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.自体造血干细胞移植后继以 CD19/22 CAR T 细胞免疫治疗中枢神经系统淋巴瘤。
Blood Cancer J. 2021 Jul 15;11(7):131. doi: 10.1038/s41408-021-00523-2.
4
CAR-T failure: beyond antigen loss and T cells.嵌合抗原受体T细胞（CAR-T）疗法失败：超越抗原丢失和T细胞因素
Blood. 2021 May 13;137(19):2567-2568. doi: 10.1182/blood.2020010462.
5
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells.新型人源化抗CD19嵌合抗原受体T细胞具有强大的抗肿瘤活性且细胞因子分泌水平低。
Mol Cancer Ther. 2021 May;20(5):846-858. doi: 10.1158/1535-7163.MCT-20-0476. Epub 2021 Feb 25.
6
Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.基因修饰的 CAR-T 细胞疗法治疗血液系统恶性肿瘤。
Int J Mol Sci. 2020 Nov 17;21(22):8655. doi: 10.3390/ijms21228655.
7
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤患者接受CAR T细胞治疗后早期进展的预测因素
Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001.
8
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
9
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
10
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.优化的串联 CD19/CD20 CAR 工程化 T 细胞治疗难治/复发 B 细胞淋巴瘤。
Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278.
Zotero 插件